Market Overview

Depomed Rejected Horizon Pharma's Takeout Bid, But Still Trades As If M&A Is Happening

Share:
Depomed Rejected Horizon Pharma's Takeout Bid, But Still Trades As If M&A Is Happening
Related DEPO
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Mid-Morning Market Update: Markets Edge Lower; Morgan Stanley Beats Q4 Estimates
DEA aims to collar production of opioids (Seeking Alpha)
Related HZNP
Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts
Earnings Scheduled For February 28, 2018
Institutional Top Ideas Series: Scopia Capital (Seeking Alpha)

In a report published Thursday, RBC Capital analyst Randall Stanicky downgraded the rating on Depomed Inc (NASDAQ: DEPO) from Outperform to Sector Perform, while raising the price target from $26 to $32. While the company reported strong Q2 results and raised its 2015 guidance, Depomed also formally reject the latest unsolicited stock offer from Horizon Pharma PLC (NASDAQ: HZNP).

Although the risk/reward appears more balanced now, the stock has risen over 98 percent year-to-date. The analyst believes that valuation could be a hurdle for other bidders, limiting upside to the stock.

On the other hand, if Depomed continues as a standalone, the analyst believes that there could be downside risk of 25 percent, adding that "the process could be drawn out as DEPO clearly does not appear to be a willing seller in an equity based deal."

With NUCYNTA scheduled to be re-launched, it would prove to be key to the value. The management sees "bockbuster" potential in the drug till the end of its patent, with 2020 revenue expected at $500 million.

In addition, according to the RBC Capital report, "[T]he company suggested it is actively engaged in discussions to acquire additional products having looked at >60 deals in 1H2015 and that tax inversion opportunities would be on the table."

Latest Ratings for DEPO

DateFirmActionFromTo
Dec 2017MizuhoUpgradesNeutralBuy
Nov 2017UBSMaintainsNeutral
Aug 2017Morgan StanleyDowngradesEqual-WeightUnderweight

View More Analyst Ratings for DEPO
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Short Ideas Downgrades Price Target Analyst Ratings Trading Ideas General Best of Benzinga

 

Related Articles (DEPO + HZNP)

View Comments and Join the Discussion!